<DOC>
	<DOCNO>NCT02340585</DOCNO>
	<brief_summary>The primary objective study demonstrate effectiveness safety Neuroform Atlas Stent System use bare metal embolic coil .</brief_summary>
	<brief_title>Neuroform Atlas IDE Study</brief_title>
	<detailed_description>The study prospective , multicenter , open-label , single arm trial design demonstrate potential treatment wide neck , intracranial , saccular aneurysm Next Generation Neuroform Stent System approve embolic coil currently market . The study evaluate percent occlusion treat target lesion angiography absence retreatment , parent artery stenosis target location 12 month . Subjects document wide neck , intracranial , saccular aneurysm arise parent artery may potentially benefit stent assist coiling , provide meet eligibility criterion .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<criteria>1 . Subject 18 80 year age 2 . Documented wide neck ( neck ≥ 4 mm dometoneck ratio &lt; 2 ) , intracranial , saccular aneurysm arise parent vessel diameter 2mm 4.5 mm , treat bare metal coil 3 . Subject legal representative willing able provide inform consent 4 . Subject willing able comply protocol followup requirement 1 . Known multiple untreated cerebral aneurysm , nontarget blister aneurysm , infundibulum , aneurysm measure &lt; 3mm three dimension assess ( height , width , depth ) require treatment study period 2 . Target lesion blister aneurysm , infundibulum , aneurysm measure &lt; 3mm three dimension assess ( height , width , depth ) 3 . Target aneurysm require Investigator intentionally leave neck remnant order preserve blood flow bifurcation branch 4 . Coiling stenting nontarget intracranial aneurysm within 30 day prior study treatment 5 . Target aneurysm anterior circulation proximal superior hypophyseal ICA 6 . Acute target aneurysm rupture le 14 day prior study treatment 7 . Hunt Hess score ≥ 3 premorbid mRS score ≥4 8 . An admission platelet count &lt; 50,000 , know coagulopathy , International Normalized Ratio ( INR ) &gt; 3.0 without oral anticoagulation therapy 9 . A known absolute contraindication angiography 10 . Evidence active cancer , terminal illness condition , opinion treat physician , would/could prevent subject complete study ( e.g. , high risk embolic stroke , atrial fibrillation , comorbidities , psychiatric disorder , substance abuse , major surgery ≤ 30 day preprocedure , etc . ) 11 . Known absolute contraindication use require study medication agent ( e.g. , heparin , aspirin , clopidogrel , radiographic contrast agent , etc . ) 12 . Female subject pregnant intend become pregnant study 13 . MoyaMoya disease , arteriovenous malformation ( ) , arteriovenous fistula ( e ) , intracranial tumor ( ) , intracranial hematoma ( ) ( unrelated target aneurysm ) 14 . Significant atherosclerotic stenosis , significant vessel tortuosity , vasospasm refractory medication , unfavorable aneurysm morphology vessel anatomy , condition ( ) , opinion treat physician , would/could prevent interfere access target aneurysm and/or successful deployment Neuroform Atlas™ Stent 15 . Previous treatment ( e.g. , surgery , stenting ) parent artery , opinion treat physician , would/could prevent interfere successful use Neuroform Atlas™ Stent System and/or successful adjunctive deployment embolic coil 16 . Previous stentassisted coil target aneurysm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Next Generation Neuroform Stent System</keyword>
	<keyword>Wide Neck , Intracranial , Saccular Aneurysms</keyword>
	<keyword>Cerebral Aneurysms</keyword>
</DOC>